BioLife Solutions, Inc. (BLFS)
After hours:
| Previous close | 24.33 |
| Open | 24.81 |
| Bid | 24.41 x 100 |
| Ask | 24.64 x 100 |
| Day's range | 24.30 - 25.03 |
| 52-week range | 8.92 - 26.73 |
| Volume | |
| Avg. volume | 337,775 |
| Market cap | 1.132B |
| Beta (5Y monthly) | 1.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
BioLife Solutions Reports Second Quarter 2024 Financial Results
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced financial results for the three and six months ended June 30, 2024 and updated revenue guidance for 2024.
- PR Newswire
BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general busi
- PR Newswire
BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced the introduction of the CryoCase, an addition to its CellSeal product line.
